The Bamlanivimab story - how it reached clinic in eight months

<p>Bamlanivimab was the first neutralising monoclonal antibody to receive emergency use authorisation from the FDA as a treatment for mild to moderate COVID-19 on 9 November 2020, 94 days after the monoclonal antibody discovery workflow began for the molecule. This achievement, says Eli Lilly, represents the shortest timeline from discovery to public usage for a monoclonal antibody to date. In February 2021, bamlanivimab administered with etesevimab received emergency use authorisation for treatment of recently diagnosed, mild to moderate COVID-19 in patients who are high risk for progression to severe COVID-19.</p> <p>Jones and Bedinger talk us through the Bamlanivimab story – and how one technology enabled this therapeutic to reach clinic in eight months during the pandemic.</p> <p>Tune in to find out how Eli Lilly strategised and built multiple collaborations enabling this Covid-19 therapeutic to reach patients in just over eight months, plus details of Carterra’s involvement in the process.</p>